MDR_Button Contact_Button News_Button  

Terms and Conditions


The following terms and conditions apply to all visitors of this website, and includes any downloaded materials. By accessing this website, visitor acknowledges acceptance of these terms and conditions.  CBA Pharma, Inc. “Company” reserves the right to change these terms and conditions from time to time at its sole discretion. By accessing the pages in this site in the future, you agree to review these terms of use to be aware of such changes, and your continued use of this site will indicate your acceptance of the terms as modified. Please read and review these terms and conditions carefully before accessing or using this website. By accessing or using this site, you acknowledge that you have read, understood and agreed to the terms of conditions. If you do not agree to the terms and conditions, you may not access or use the website.

The user of this website agrees to indemnify, defend and hold harmless the Company, its affiliates, officers, directors, employees, agents, suppliers and third party partners from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of these Terms and Conditions.

In no event shall the Company be liable for any damages (including, without limitation, damages for loss of data or profit, or due to business interruption,) arising out of the use or inability to use the materials on the Company’s website, even if the Company or a authorized representative of the Company has been notified orally or in writing of the possibility of such damage.

Forward Looking Statements
This website may contain “forward-looking statements”, within the meaning of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Act and Section 21E of the Securities Exchange Act of 1934, as amended). All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events and they are subject to numerous known and unknown risks and uncertainties which could cause actual events or results to differ materially from those projected by such forward-looking statements as a result of various factors, including, without limitation, general economic trends, product demand and market acceptance, technological advances, availability of resources, domestic and foreign competition, governmental regulations and policies (including, but not limited to, changes in FDA rules, regulations and policy, as well as failure to receive marketing approval from the FDA, which would result in the inability to commercialize CBT-1® The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any forward looking statements contained herein to reflect future events or developments.

The Company has made all reasonable efforts to provide accurate information on its website. However, we cannot and do not warrant the accuracy, completeness or timeliness of the information contained therein. In addition, some of the information contained in this site is time sensitive and you should not assume the information contained herein is accurate or current as of any date, other than the date indicated. We disclaim any duty to update such information. Nothing contained in the Company’s website constitutes advice and any decisions based on information contained in this site are the sole responsibility of the visitor.

No confidential relationship shall be established in the event that any user of this website makes any oral written or electronic response to the Company(such as feedback, questions, comments, suggestions, ideas, etc.). Such response shall be considered non-confidential, and the Company shall have no obligation with respect thereto.

The Company respects the privacy of its website users. Please refer to the Company’s Privacy Policy that explains users' rights and responsibilities with respect to information that is disclosed on this website.

Links to Third Party Sites
This website may contain links to third party sites. Access to any other Internet site linked to this website is at the visitor's own risk and the Company is not responsible for the accuracy or reliability of any information, data, opinions, advice or statements made on these sites. The Company provides these links merely as a convenience and the inclusion of such links does not imply an endorsement or warranty of those links or their associated websites.

Trademarks and Copyrights
All trademarks whether or not appearing in large print or with the trademark symbol, are trademarks of the Company, and its affiliates, unless otherwise noted. The use or misuse of these trademarks or any other materials, except as permitted herein, is expressly prohibited and may be in violation of copyright law, trademark law, the law of slander and libel, the law of privacy and publicity, and communications regulations and statutes. Please be advised that the Company actively and aggressively enforces its intellectual property rights to the fullest extent of the law. The entire contents of this website are subject to copyright protection. The contents of this  website may not be copied other than for noncommercial individual reference with all copyright or other proprietary notices retained, and thereafter may not be recopied, reproduced or otherwise redistributed. Except as expressly provided above, you may not otherwise copy, display, download, distribute, modify, reproduce, republish or retransmit any information, text or documents contained in this website or any portion thereof in any electronic medium or in hard copy, or create any derivative work based on such images, text or documents, without the express written consent of the Company. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of the Company, or any third party.

Revised October 2012





Column Header 1 Column Header 2 Column Header 3
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, was developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant.
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.


© CBA Pharma, Inc. 2014 All Rights Reserved Contact Us Privacy Statement Terms and Conditions